$MRK failed with cCAM because of a dosage miss which then decided to stop further clinical development of MK-6018 also known as “CM-24”. $KTOV’s powerful drug in Phase 1 with Bristol Myers Squibb. CM-24 was acquired by $KTOV in 2019. https://t.co/2uLZbp2shp